On 24 August the FDA approved Johnson & Johnson's Imaavy for warm autoimmune hemolytic anemia — the first therapy ever approved for the disease. wAIHA has been treated for decades with corticosteroids, broad immunosuppressants and B-cell drugs, none of them approved for it. A first-in-disease label is the strongest regulatory event a company can announce, and J&J does not get to announce one often.
Underneath it is a very small trial. Imaavy's prescribing information, revised two days after the approval, gives the pivotal result in whole patients: nine of 38 on the approved dose achieved a durable hemoglobin response, against three of 39 on placebo. That is 23.7% against 7.7%, a difference of 16.0 percentage points, p = 0.015 — and a 95% confidence interval running from 0.1 points to 31.9.
The approval is real and the endpoint was met. But an interval whose floor sits a tenth of a point above nothing is not a number anyone can underwrite a launch on, and the figures that decide what this label is worth are not the response rate at all. They are the size of the disease and the price of the drug, both of which sit in the card at the top of this piece alongside the trial result.
What Imaavy is, and who it is for
Imaavy is a neonatal Fc receptor (FcRn) blocker. FcRn is the receptor that recycles immunoglobulin G back into circulation instead of letting it be broken down; blocking it lowers circulating IgG. That single mechanism is why one drug addresses two unrelated-sounding diseases — both are driven by IgG autoantibodies.
It has two approved indications in the United States, both in patients 12 years and older:
Generalized myasthenia gravis, approved April 2025, in patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. In gMG the immune system attacks the proteins that carry the signal from nerve to muscle, producing fluctuating weakness — drooping eyelids, difficulty speaking and swallowing, weak limbs, and in severe cases impaired breathing. The European Commission authorised the same indication on 1 December 2025, there worded as an add-on to standard therapy; the US label carries no such add-on wording.
Warm autoimmune hemolytic anemia, added 24 August 2026, in patients currently or previously treated with corticosteroids. In wAIHA, IgG antibodies bind red blood cells at body temperature and mark them for destruction, causing anemia, fatigue, jaundice and, in serious cases, a transfusion requirement. This is the indication that had never been filled: it is the first therapy ever approved for the disease.
The distinction matters for everything below. The wAIHA label is the smaller of the two by patient count, and the peak-sales figure J&J has published covers the drug across every indication — so a reader who reads that forecast as a wAIHA number is reading the wrong disease.
The points
- 9 of 38 versus 3 of 39. The approved-dose arm and placebo, from the label. The FDA rounds them to 24% and 8%.
- 16.0 points of difference, 95% CI 0.1 to 31.9. Disclosed in the label. The interval is 31.8 points wide and its floor is a tenth of a point.
- The other dose arm did not work. The FDA states plainly that the 15 mg/kg every-two-weeks arm "did not lead to a higher proportion of patients with a durable hemoglobin response compared to placebo." Both arms deliver 7.5 mg/kg a week — 30 every four weeks, 15 every two — so the two schedules are identical in milligrams a week and opposite in outcome. That is either a real pharmacodynamic finding about how far IgG has to fall between doses, or it is noise; a trial with fewer than 40 patients an arm cannot tell you which.
- The endpoint is strict and composite. Hemoglobin at or above 10 g/dL, up at least 2 g/dL from baseline, held across three consecutive visits over at least 28 days starting by Week 16, and no rescue therapy. 23.7% is not "it worked in a quarter of patients"; it is the share clearing all four conditions at once.
- Approved at 30 mg/kg every four weeks, after an identical 30 mg/kg first infusion. Thirteen infusions a year.
- $12,480 for a 1,200 mg vial, the list price J&J set when Imaavy launched in myasthenia gravis in April 2025 and called "competitively priced."
Two curves: how many patients, and what each one costs
The response rate is the number everyone quoted. It is not the number that matters. Multiply the approved regimen by the disclosed vial price and Imaavy costs $4,056 per kilogram of body weight per year at list — 390 mg/kg a year at $10.40 a milligram. For a 70 kg adult that is about $284,000 a year; for an 80 kg one, exactly two 1,200 mg vials an infusion and no rounding, $324,480. That is ours, arithmetic on J&J's list price; it assumes the smaller 300 mg vial is priced in proportion, since J&J published only the large one, and it is before every discount and rebate nobody publishes.
The other curve is the disease. J&J's own release puts wAIHA at about 1 in 8,000 people living with it, which against a US population of 341.8 million is roughly 43,000 Americans. The FDA gives incidence instead — 1 to 3 new cases per 100,000 a year, so 3,400 to 10,300 new American patients annually. The two are compatible: a prevalence of 12.5 per 100,000 against that incidence implies patients carry the disease for four to twelve years, which is what a relapsing autoimmune anemia does.
Put the curves together and the label's commercial ceiling stops being abstract:
| Americans on Imaavy for wAIHA | Share of the ~43,000 | US sales at list |
|---|---|---|
| 500 | 1.2% | $142M |
| 1,000 | 2.3% | $284M |
| 3,520 | 8.2% | $1.0B |
| 10,000 | 23.4% | $2.8B |
J&J told investors in July that it now has 28 products and platforms each above $1 billion in annual sales. On this arithmetic, the wAIHA label alone joins that list at about 3,500 American patients on therapy at any one time — 8% of everyone in the country living with the disease, at full list price, with no ex-US contribution. That is the honest shape of a rare-disease first approval: not a rounding error, and not automatic either. It is a market-share question with a very small numerator.
J&J's own forecast is a patient count
The company has already published its answer. At the myasthenia gravis launch J&J said Imaavy's sales could eventually eclipse $5 billion a year at peak, across every indication. Run that through the same price and it is about 17,600 patients on the drug at once, worldwide, at US list prices — and since ex-US prices are lower, the real headcount is higher than that.
Set 17,600 against 43,000 Americans with wAIHA and the arithmetic tells you what the $5 billion actually rests on. It cannot be this label. It needs myasthenia gravis, it needs the rheumatologic and maternal-fetal programmes J&J says nipocalimab is being investigated across, and it needs those to be approved, which they are not. Imaavy has two approved indications today, and the value of the franchise is the count of labels, not the size of any one of them.
What it does to this year, and to the model
Nothing, and the size of the nothing is the point. On the 15 July call CFO Joseph Wolk listed the second-half catalysts and named this one: J&J anticipated FDA approval for Imaavy in wAIHA. The raised full-year outlook — a $101.1 billion reported-sales midpoint, which we covered at the print — was set with the approval already assumed. It is not an upgrade to the guide; it is the guide arriving on schedule.
Nor does it land on anything our J&J model carries. That model runs eight verticals, the four Innovative Medicine therapeutic areas and the four MedTech franchises J&J publishes each quarter. Imaavy has no line of its own in it, because it has none in J&J's disclosure either — the company folds it into "other immunology," which it named in July as a growth driver alongside ICOTYDE without giving a number for either. The Immunology vertical it sits in is a $3.84 billion quarter driven by TREMFYA's ramp against the STELARA biosimilar cliff, and the model's $219.68 base against the $273.04 price it was struck at on 27 August turns on the exit multiple, not on any single launch. A wAIHA label reaching $1 billion would be worth about 1% of the revenue base. Nothing here changes an assumption we hold.
What would change the conclusion
- A confirmatory result in more than 38 patients. The 144-week open-label extension and any post-marketing commitment are the only things that will narrow a 0.1-to-31.9 interval. Until one reports, the effect size is a range, not a point.
- Real-world persistence. A 24-week response rate is not a discontinuation curve. What share of patients started on Imaavy are still on it at two years is the figure that converts prevalence into revenue, and nobody has it yet.
- Any Imaavy number in J&J's segment disclosure. The company reports "other immunology" as a residual. The quarter it breaks Imaavy out is the quarter it has decided the drug is separately material.
- The next label. The $5 billion peak forecast needs indications that are not approved. A rheumatologic or maternal-fetal filing moving to review does more to that forecast than anything in this trial did.
Both approved indications, their antibody and corticosteroid qualifiers, the 12-and-over age limit, the FcRn mechanism, and every trial figure — response rates, the 16.0-point difference and its interval, the endpoint definition and the every-four-weeks regimen — are in Imaavy's US prescribing information as revised 26 August 2026. The European Commission's 1 December 2025 authorisation and its add-on wording are from J&J's announcement of it. The failure of the 15 mg/kg arm and the incidence range are the FDA's; the 1-in-8,000 prevalence and the account of off-label practice are J&J's approval release of 24 August. The vial price and the "could eventually eclipse $5 billion" peak forecast are J&J's from the April 2025 myasthenia gravis launch, and that forecast spans every indication rather than wAIHA alone. Everything derived — cost per kilogram, per-patient year, patient counts and prevalent population against a 341.8 million Census estimate — is ours, at undiscounted US list price. The quarterly segment figure and $101.1 billion outlook are as reported and guided 15 July 2026. Model figures are assumptions of ours.
